PMV Pharmaceuticals (NASDAQ:PMVP) stock surged 16% after the company released encouraging interim results from its Phase 2 PYNNACLE trial, evaluating rezatapopt in patients with various solid tumors carrying the TP53 Y220C mutation.
The precision oncology study showed a 33% overall response rate among 97 evaluable patients across eight tumor types, with a median response duration of 6.2 months. Response rates were especially strong in the ovarian cancer cohort, which achieved 43%, with patients experiencing a median response of 7.6 months.
The trial confirmed tumor responses in patients with TP53 Y220C mutated and KRAS wild-type tumors, covering ovarian, lung, breast, endometrial, head and neck, colorectal, gallbladder, and ampullary carcinomas. Across all cohorts, the median time to response was 1.4 months.
Most treatment-related adverse events were mild to moderate (Grade 1-2), including nausea, fatigue, and certain laboratory marker elevations. The company also reported that taking rezatapopt with food improved gastrointestinal tolerability compared with Phase 1 results.
Following discussions with the FDA, PMV plans to enroll an additional 20-25 platinum-resistant or refractory ovarian cancer patients by the end of the first quarter of 2026. The company aims to submit a New Drug Application for this indication by Q1 2027.
PMV Pharmaceuticals stock price
This content is for informational purposes only and does not constitute financial, investment, or other professional advice. It should not be considered a recommendation to buy or sell any securities or financial instruments. All investments involve risk, including the potential loss of principal. Past performance is not indicative of future results. You should conduct your own research and consult with a qualified financial advisor before making any investment decisions.